Venture-Backed Inotek Raises $40M In Downsized IPO
Inotek Pharmaceuticals Corp., a venture capital-backed biotechnology company developing an eye drop treatment for glaucoma, raised $40 million in a downsized initial public offering after slashing the price of its public...To view the full article, register now.
Already a subscriber? Click here to view full article